Trial sponsors have shared these lung cancer clinical trials that are enrolling participants to help advance lung cancer science. Most medications and treatments currently available are thanks to patients who went through clinical trials to prove the effectiveness and safety of the treatment being studied.

Clinical trials have eligibility requirements to join so that participants remain safe, while having a likelihood of success when it comes to treatment.

If you’re interested in joining one of the clinical trials below, make sure to talk with your doctor and ask if they think it would be helpful for your treatment. Some patients may have additional health problems that could be made worse by treatments used in a clinical trial.

Note: The status of each trial may change with time. Please reach out to the contact listed in each trial opportunity to get the most up-to-date information. 

Available Clinical Trials

ALK NSCLC - neladalkib

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

Contact:

Phone Number: 857-357-7000 
Email: [email protected]

About this trial:

This is a multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma Kinase (ALK) positive, advanced Non-Small Cell Lung Cancer (NSCLC). Patients will be randomized in a 1:1 ratio (approximately 225 in each arm) to receive either neladalkib (NVL-655) or alectinib. 

Who can participate:

Patients must have documented ALK rearrangement via testing of tissue or blood and presence of measurable disease by RECIST 1.1. Patients cannot have a known oncogenic driver alteration other than ALK or the presence of brain metastases associated with progressive neurological symptoms or requiring increasing dose of corticosteroids to control CNS disease. 

Learn More

SCLC - immunotherapy + chemotherapy

Clinical Study of an Investigational Immunotherapy for First line Treatment of Advanced Cancer (TIGOS)

Contact:

Phone Number: 855.907.3286
Email: [email protected]

About this trial:

This is a randomized, Phase 3 global clinical study evaluating an investigational immunotherapy given with chemotherapy compared to standard of care immunotherapy given with chemotherapy in people with extensive-stage small cell lung cancer who have not received prior treatment for advanced disease.

Participants who qualify will be assigned to receive one of the two treatment approaches.

The purpose of the study is to compare the safety and effectiveness of the investigational treatment and to help determine whether it may offer benefit for patients in the future.

Who can participate:

The study is open to patients with extensive-stage small cell lung cancer who have not received prior systemic treatment for advanced disease and are able to meet the study requirements.
 

Learn More

NSCLC - nivolumab and relatlimab

Clinical Study of Nivolumab and Relatlimab for First line Treatment of Advanced Non Small Cell Lung Cancer (RELATIVITY 1093)

Contact:

Phone Number: 855.907.3286
Email: [email protected]

About the trial:

This is a randomized, Phase 3 global clinical study evaluating an investigational immunotherapy combination given with chemotherapy compared to a standard immunotherapy plus chemotherapy in people with advanced or recurrent non small cell lung cancer (NSCLC) who have not received prior treatment for advanced disease. 

Participants who qualify will be assigned to receive one of the two options.

The purpose of the study is to compare the safety and effectiveness of these approaches and to help determine whether the investigational treatments may offer benefit for patients in the future.
 

Learn More

*These trials are listed for a period of 3 months.